Results 141 to 150 of about 65,156 (262)

Basophil FceRI expression-A management tool in anti-IgE treatment of allergic asthma. [PDF]

Pediatr Pulmonol
Rubak SLM, Bonne NL, Hjerrild BE, Hoffmann HJ.   +3 more
europepmc   +1 more source

Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy. [PDF]

Drug Des Devel Ther, 2020
Kariyawasam HH, James LK.
europepmc   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

LP-003, a novel high-affinity anti-IgE antibody for inadequately controlled seasonal allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical trial. [PDF]

Clin Transl Allergy
Guan K, Liu S, Feng Y, Li L, Zhu X, Bill NC, Ma H, Yang J, Han C, Liu H, Wei Q, Shi H, Wang X.   +12 more
europepmc   +1 more source

Vernal Keratoconjunctivitis: A Case of Anti-IgE Treatment with Short-Lasting Remission. [PDF]

Case Rep Ophthalmol, 2020
Gatta A, Della Valle L, Farinelli A, Scarano G, Lumaca A, Cavallucci E, Di Gioacchino M, Paganelli R.   +7 more
europepmc   +1 more source

Early Risk Assessment and Recognition of Allergies in Children: Rationale, Methodology, and Proposed Algorithms

Allergy, EarlyView.
ABSTRACT Background Atopic diseases—including atopic dermatitis (AD), food allergy (FA), allergic rhinitis (AR), and asthma—are the most common chronic conditions in childhood and adolescence, affecting up to 30% of the global population. In Germany alone, more than 2.1 million children and adolescents are affected.
E. Hamelmann, B. Schaub, K. Beyer, K. Blümchen, M. Gerstlauer, M. V. Kopp, L. Lange, S. Lau, N. Maison, H. Ott, S. M. Schmidt, T. Spindler, C. Traidl‐Hoffmann, C. Vogelberg   +13 more
wiley   +1 more source

Reduced Effectiveness of Anti-IgE Treatment Among Adults with Severe Asthma with Older Age of Asthma Onset: Results from the CHRONICLE Study. [PDF]

J Asthma Allergy
Ledford DK, Carr WW, Moore WC, Lugogo NL, Mohan A, Chipps B, Mackie AR, Lindsley AW, Spahn J, Ambrose CS.   +9 more
europepmc   +1 more source

The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors. [PDF]

J Clin Invest, 2020
Balbino B, Herviou P, Godon O, Stackowicz J, Goff OR, Iannascoli B, Sterlin D, Brûlé S, Millot GA, Harris FM, Voronina VA, Nadeau KC, Macdonald LE, Murphy AJ, Bruhns P, Reber LL.   +15 more
europepmc   +1 more source

Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract—the B Cell Side

Allergy, EarlyView.
ABSTRACT Allergic diseases are on the rise worldwide, driven by respiratory epithelial barrier dysfunction that promotes sensitization to inhalant allergens such as pollen, dust mites, pet dander, and fungal spores. These antigens trigger IgE‐mediated immune responses that lead to diseases such as allergic rhinitis (AR) and asthma.
Ola Grimsholm, Mohammed Zghaebi, Bita Hambrecht, Tanja Kalic, Christopher C. Udoye, Rudolf Manz, Barbara Bohle, Katarzyna M. Sitnik, Julia Eckl‐Dorna, Heimo Breiteneder   +9 more
wiley   +1 more source

Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study. [PDF]

Am J Respir Crit Care Med
Djukanović R, Brinkman P, Kolmert J, Gomez C, Schofield J, Brandsma J, Shapanis A, Skipp PJS, Postle A, Wheelock C, Dahlen SE, Sterk PJ, Brown T, Jackson DJ, Mansur A, Pavord I, Patel M, Brightling C, Siddiqui S, Bradding P, Sabroe I, Saralaya D, Chishimba L, Porter J, Robinson D, Fowler S, Howarth PH, Little L, Oliver T, Hill K, Stanton L, Allen A, Ellis D, Griffiths G, Harrison T, Akenroye A, Lasky-Su J, Heaney L, Chaudhuri R, Kurukulaaratchy R, SoMOSA study team and the U-BIOPRED study team.   +40 more
europepmc   +1 more source